ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Treatment of FIGO 2018 stage IIIC cervical cancer with different local tumor factors

Ye, Yanna; Li, Zhiqiang; Kang, Shan; Yang, Yongxiu; Ling, Bin; Wang, Li; Yao, Jilong; Li, Pengfei; Wang, Xueqin; Gong, Shipeng; Fan, Huijian; Kong, Yanxiang; Cao, Yuye; Lang, Jinghe; Liu, Ping*; Chen, Chunlin*东莞理工学院; 广州医学院; 南方医科大学; 兰州大学; 河北医科大学; 郑州大学; 中山大学; 中国医学科学院北京协和医院; 1; 5
BMC CANCER2023-5-9DOI: 10.1186/s12885-023-10801-w
7阅读
引用收藏
分享

摘要

BackgroundTo compare the oncological outcomes of patients with FIGO 2018 stage IIIC cervical cancer (CC) involving different local tumor factors who underwent abdominal radical hysterectomy (ARH), neoadjuvant chemotherapy and radical surgery (NACT), or radical chemoradiotherapy (R-CT).MethodsBased on tumor staging, patients with stage IIIC were divided into T1, T2a, T2b, and T3 groups. Kaplan-Meier and Cox proportional hazards regression analysis were used to compare their overall survival (OS) and disease-free survival (DFS) of 5 years.ResultsWe included 4,086 patients (1,117, 1,019, 869, and 1,081 in the T1, T2a, T2b, and T3 groups, respectively). In the T1 group, NACT was correlated with a decrease in OS (hazard ratio [HR] = 1.631, 95% confidence interval [CI]: 1.150-2.315, P = 0.006) and DFS (HR = 1.665, 95% CI: 1.255-2.182, P < 0.001) than ARH. ARH and NACT were not correlated with OS (P = 0.226 and P = 0.921) or DFS (P = 0.343 and P = 0.535) than R-CT. In the T2a group, NACT was correlated with a decrease in OS (HR = 1.454, 95% CI: 1.057-2.000, P = 0.021) and DFS (HR = 1.529, 95% CI: 1.185-1.974, P = 0.001) than ARH. ARH and NACT were not correlated with OS (P = 0.736 and P = 0.267) or DFS (P = 0.714 and P = 0.087) than R-CT. In the T2b group, NACT was correlated with a decrease in DFS (HR = 1.847, 95% CI: 1.347-2.532, P < 0.001) than R-CT nevertheless was not correlated with OS (P = 0.146); ARH was not correlated with OS (P = 0.056) and DFS (P = 0.676). In the T3 group, the OS rates of ARH (n = 10), NACT (n = 18), and R-CT (n = 1053) were 67.5%, 53.1%, and 64.7% (P = 0.941), and the DFS rates were 68.6%, 45.5%, and 61.1%, respectively (P = 0.761).ConclusionR-CT oncological outcomes were not entirely superior to those of NACT or ARH under different local tumor factors with stage IIIC. NACT is not suitable for stage T1, T2a, and T2b. Nevertheless ARH is potentially applicable to stage T1, T2a, T2b and T3. The results of stage T3 require confirmation through further research due to disparity in case numbers in each subgroup.

学科与关键词

关键词
Cervical cancerFIGO 2018 stage IIICLocal tumor factorsTreatment
相关
加载中…

文献加载失败,请重试

重试

发表信息

论文状态
公开发表
期刊
BMC CANCER
发表日期
2023-05-09
卷期
第 23 卷, 第 1 期
页码
421
DOI
10.1186/s12885-023-10801-w
语言
ENGLISH
成果收录
SCIE
资助标注
National Science and Technology Support Program of China [2014BAI05B03]; National Natural Science Fund of Guangdong [2015A030311024]; Science and Technology Plan of Guangzhou [158100075]

作者

  • Y

    Ye, Yanna (第一作者)

    dongguan polytech · southern med univ

  • L

    Li, Zhiqiang

    southern med univ

查看全部 16 位作者收起作者
  • K

    Kang, Shan

    hebei med univ

  • Y

    Yang, Yongxiu

    1 · lanzhou univ

  • L

    Ling, Bin

    china japan friendship hosp

  • W

    Wang, Li

    zhengzhou univ

  • Y

    Yao, Jilong

  • L

    Li, Pengfei

    southern med univ

  • W

    Wang, Xueqin

    5 · southern med univ

  • G

    Gong, Shipeng

    southern med univ

  • F

    Fan, Huijian

    guangzhou med univ

  • K

    Kong, Yanxiang

    sun yat sen univ

  • C

    Cao, Yuye

    southern med univ

  • L

    Lang, Jinghe

    peking union med coll hosp · southern med univ

  • L

    Liu, Ping (通讯)

    southern med univ

  • C

    Chen, Chunlin (通讯)

    southern med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417